ENSYSCE BIOSCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements of -$230.00 thousand for the 12-month period ending 2020-12-31, per its 10-K/A filed 2021-06-08.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements · last filed 2021-06-08
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2020 was -$230.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 12 month |
|---|---|
| 2020-12-31 | -$230.00K 10-K/A · filed 2021-06-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |